Oncology testing continues to advance, driven by emerging scientific insights and the need to align with evolving clinical guidelines. This session will discuss the value of driving improved actionability through the optimized delivery of guideline-based assays for biomarker evaluation in both solid tumors and hematologic malignancies—from design to final reporting. We will examine key considerations in target selection and reporting that help support broader treatment options and more personalized therapeutic strategies.
